IPF treatment shows early promise in trial for reversing scarring
CS014, a treatment candidate for idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in healthy volunteers in a Phase 1 clinical trial, according to new data from developer Cereno Scientific. Further, the experimental medication reached levels in the bloodstream that the company predicts will…